NDLI: Lapatinib: current status and future directions in breast cancer.

Please wait, while we are loading the content...

Lapatinib: current status and future directions in breast cancer.

Content Provider	Semantic Scholar
Author	Moy, Beverly Goss, Paul E.
Copyright Year	2006
Abstract	Lapatinib is an oral receptor tyrosine kinase inhibitor, targeting both the ErbB-1 and ErbB-2 receptors. Pre-clinical in vitro and in vivo models indicate that lapatinib is active as monotherapy, synergistically in combination with trastuzumab, and in trastuzumab-resistant cell lines. Early clinical trials also provide evidence in patients that lapatinib is active against breast cancer. This paper reviews results of phase II and III clinical trials of lapatinib in metastatic breast cancer, evidence for its potential in patients with brain metastases, and current clinical trials as adjuvant treatment in early-stage disease. Our improved understanding of the biology of breast cancer and the use of biomarkers for identification of specific subtypes is allowing us to bring patient-specific novel therapies such as lapatinib to the clinic.
Starting Page	2547
Ending Page	2554
Page Count	8
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://theoncologist.alphamedpress.org/content/11/10/1047.full.pdf
PubMed reference number	17110623v1
Volume Number	11
Issue Number	10
Journal	The oncologist
Language	English
Access Restriction	Open
Subject Keyword	Acne Vulgaris Adjuvant Study Adverse event Adverse reaction to drug Biological Markers Carcinoma breast stage IV Cardiotoxicity Conflict (Psychology) Cultured Cell Line Diarrhea Dry skin Dual EGFR protein, human Exanthema Fatigue In Vitro [Publication Type] Mammary Neoplasms Metastatic malignant neoplasm to brain Nausea Neoplasm Metastasis Paget's Disease, Mammary Patients Pharmaceutical Adjuvants Protein Tyrosine Kinase Protein-tyrosine kinase inhibitor Pruritus Receptor Protein-Tyrosine Kinases Review [Publication Type] Subtype (attribute) Therapeutic procedure capecitabine cellular targeting erbB-2 Receptor lapatinib trastuzumab
Content Type	Text
Resource Type	Article

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in